Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
2019 · Clinical Cancer Research · 59 citations
https://doi.org/10.1158/1078-0432.ccr-19-1164
A
Alex Pearson
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
135
Papers
2.6K
Citations
18
h-index
19
i10-index
Alex Pearson is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Advanced Breast Cancer Therapies & PARP inhibition in cancer therapy & Estrogen and related hormone effects. The author has an h-index of 18, co-authored 115 publications.
ORCID: 0000-0002-5854-193XPapers by this author
worksMolecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
2018 · British Journal of Cancer · 19 citations
https://doi.org/10.1038/s41416-018-0345-x
The Relationship between ‘Early’ and ‘Late’ Radiation-induced Skin Reactions as Seen in Two Strains of Mice That Differ in Radiosensitivity
1983 · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · 9 citations
https://doi.org/10.1080/09553008314551291
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
2018 · Breast Cancer Research and Treatment · 8 citations
https://doi.org/10.1007/s10549-018-4798-7
Radiotherapy fraction size sensitivity is modulated by DNA repair systems
2010 · Breast Cancer Research · 0 citations
https://doi.org/10.1186/bcr2549
Figure 1 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer
2024 · 0 citations
https://doi.org/10.1158/2159-8290.25183894.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat